Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A 1C and Weight in Patients with Type 2 Diabetes

Background: No head-to-head comparisons of semaglutide formulations currently exist in the literature. In practice, many may think that oral and injectable semaglutide formulations are interchangeable, although there is currently limited real-world data to determine whether this is accurate. Objective: ) and weight in patients with type 2 diabetes (T2D). Methods: (%) and weight (kg) from baseline to 6 months between patients receiving oral versus injectable semaglutide, stratified according to highest dose received. Secondary outcomes included frequency of dose reductions and discontinuations, achievement of clinical goals, and presence of an embedded clinical pharmacist at patients' primary care office. Results: = 0.312). Adverse events (AEs) occurred more frequently with oral semaglutide than with injectable semaglutide (16.7% vs 4.9%). Discontinuation due to AEs was more common with oral semaglutide. Conclusion: or weight between the 2 formulations. Rates of AEs and discontinuation were more common in the oral semaglutide group.